I see a co-promotion partnership of AMGN with CYTK, with AMGN handling the marketing and providing a sales force for the continuity of care approach with OM IV / oral formulations. . CYTK may kick in their own noobie sales force to retain more proceeds, but sales is not their core competency. IMHO I don't see a buyout untill a foothold is established and revenues are realized. BP's are a conservative timid bunch by nature and like to have a solid rational to present to shareholders before merging etc. A solid cash flow helps..